Dr. Patrick Hwu welcomes Dr. Sandra Demaria, Professor of Radiation Oncology and Pathology at Weill Cornell Medicine and a global leader in cancer immunology. Dr. Demaria shares her pioneering research demonstrating how radiotherapy can transform tumors unresponsive to immune checkpoint inhibitors into responsive ones—a discovery that has reshaped cancer treatment strategies worldwide.   Recorded live from the 2025 SITC Annual Meeting, this episode highlights the emerging science shaping the future of immunotherapy, including late-breaking abstracts and press program findings presented at the conference. As the current vice president of SITC, Dr. Demaria discusses the evolving synergy between radiation and immunotherapy, insights from studying the immune microenvironment and the translation of her discoveries into ongoing clinical trials. She also reflects on the collaborative energy that defines SITC and continues to drive the next generation of combination immunotherapies.

Dr. Patrick Hwu welcomes Dr. Mario Sznol, professor of medicine at Yale School of Medicine and co-director of the Cancer Immunology Program at Yale Cancer Center. Dr. Sznol shares his journey from early work with high-dose interleukin-2 at the NCI to leading pivotal trials in checkpoint blockade and combination immunotherapies. He discusses the science behind cytokines, immune checkpoints, bispecific antibodies, and T-cell therapies, along with strategies for managing immune-related toxicities. Dr. Sznol also reflects on the collaborative, innovative spirit of the field and the next wave of therapies poised to further transform cancer treatment. What You’ll Learn from Dr. Sznol How the earliest trials of interleukin-2 paved the way for modern immunotherapy The inside story of developing and combining anti–PD-1 and anti–CTLA-4 checkpoint inhibitors Why durable cures in metastatic melanoma and kidney cancer were once thought impossible — and how that changed How scientists learned to manage immune-related toxicities and make combination immunotherapy safer What’s next in the field: bispecific antibodies, T-cell engagers, and engineered cell therapies The importance of collaboration, persistence, and even a little fun (“ImmunoTennis”) in advancing science Access more show notes, links and transcript here: https://www.moffitt.org/about-moffitt/podcasts/immunoverse/cytokines-to-checkpoint-blockade

Dr. Patrick Hwu welcomes Dr. Fred Locke, chair of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Dr. Locke shares his personal and professional journey into CAR T-cell therapy, shaped in part by his own father’s cancer battle. A leader in pivotal clinical trials, Dr. Locke explains how engineered T cells are transforming lymphoma treatment — offering durable, sometimes curative responses. He discusses the science behind CAR T-cell manufacturing, trial design and its growing applicatio to diseases like multiple myeloma, along with future innovations in cellular immunotherapy. What You’ll Learn from Dr. Locke How a personal family experience inspired Dr. Locke’s passion for immunotherapy The story behind pivotal CAR T clinical trials (ZUMA-1 and ZUMA-7) and their FDA approvals What makes CAR T therapy so effective in blood cancers — and the challenges with solid tumors Innovative approaches on the horizon: donor-derived CAR Ts, TIL therapy, and engineered TCR therapies Why diet, exercise, and prehabilitation may improve immune cell therapy outcomes How Moffitt is scaling CAR T for outpatient treatment and community hospital access Access more show notes, links and transcript here: https://www.moffitt.org/about-moffitt/podcasts/immunoverse/future-of-cellular-treatments/

Dr. Patrick Hwu sits down with Dr. Thomas Gajewski, a leader in tumor immunology at the University of Chicago. Dr. Gajewski discusses his pioneering work defining “hot” versus “cold” tumors — an insight that transformed how immunotherapists understand tumor response. The conversation dives into how the tumor microenvironment, patient genetics and even the gut microbiome shape immune activity in cancer. His work continues to drive strategies to turn cold tumors into responsive ones, giving new hope to patients across all cancer types.  What You’ll Learn from Dr. Gajewsk Origins of the hot vs cold tumor concept and its impact on immunotherapy. How checkpoint inhibitors revive immune responses in T-cell–infiltrated (“hot”) tumors. Challenges of cold tumors and strategies to convert them into hot, immune-responsive tumors. Pioneering work linking the gut microbiome to immunotherapy response. The significance of interdisciplinary research, from tumor genetics to immunology.Humanizing science: the role of music and culture in building community and sustaining belief. Access more show notes, links and transcript here: https://www.moffitt.org/about-moffitt/podcasts/immunoverse/hot-vs-cold-tumors/

Dr. Patrick Hwu welcomes Dr. Elizabeth Jaffee of Johns Hopkins, a renowned leader in cancer immunotherapy. Dr. Jaffee shares the personal and scientific journey that led her to tackle one of oncology’s toughest challenges: pancreatic cancer. From her early fascination with virology to pioneering the use of genetically modified tumor vaccines, she has pushed the boundaries of what’s possible in cancer prevention and treatment. Dr. Jaffee also discusses efforts to use immunotherapy earlier — even preventively — and explores how AI and multi-modal data could revolutionize cancer risk prediction and early detection.

Host Dr. Patrick Hwu sits down with immunotherapy pioneer Dr. James Mulé to discuss the origins and evolution of T cell therapies, groundbreaking discoveries at the NCI, and the translation of research to patient care at Moffitt Cancer Center.

Host Dr. Patrick Hwu sits down with trailblazing immunologist Dr. Phil Greenberg of Fred Hutchinson Cancer Center to explore how engineered T cells are revolutionizing cancer treatment. From early experiments in synthetic biology to today's clinical breakthroughs, Dr. Greenberg shares his decades-long journey to harness and rewire the immune system, turning obstacles into opportunities and transforming science fiction into standard of care.

In the premiere episode of The ImmunoVerse, host Dr. Patrick Hwu sits down with pioneering physician-scientist Dr. Steven A. Rosenberg, Chief of Surgery Branch at the National Cancer Institute. Together, they explore the roots of Dr. Rosenberg’s fascination with the immune system, tracing his remarkable journey from early scientific curiosity to the groundbreaking immunology discoveries that have reshaped cancer treatment.

Welcome to The ImmunoVerse™, a podcast exploring the past, present, and future of immunotherapy. In each episode, join Dr. Patrick Hwu as he sits with pioneering experts who are shaping the future of cancer treatment—uncovering breakthroughs, challenges, and the science driving this life-saving innovation. Don’t miss out—subscribe to The ImmunoVerse™ now and listen on your favorite podcast platforms!